Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Clinvest Merck |
---|---|
Information provided by: | Clinvest |
ClinicalTrials.gov Identifier: | NCT00772473 |
To assess CGRP levels in saliva through the evolution of migraine.
Condition | Intervention |
---|---|
Headache, Migraine |
Other: subjects usual triptan treatment |
Study Type: | Observational |
Study Design: | Case-Only, Prospective |
Official Title: | Correlation of Calcitonin Gene-Related Peptide (CGRP) Levels in Saliva With the Evolution of an Attack of Migraine |
saliva
Estimated Enrollment: | 30 |
Study Start Date: | February 2008 |
Groups/Cohorts | Assigned Interventions |
---|---|
1 group, usual acute triptan treatment |
Other: subjects usual triptan treatment
Subjects will treat 1 migraine attack with their usual triptan
|
The release of CGRP is assumed to be initiated early in the migraine process and increases as the headache intensifies. Levels of CGRP will be measured during the premonitory, mild, moderate, and severe phases of a single migraine attack and compared to the baseline value determined when the subject was headache free. Understanding of the clinical evolution of migraine CGRP release may have significant implications in acute treatment.
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Patients at a mid west headache specialty clinic
Inclusion Criteria:
Exclusion Criteria:
Contact: Melody Knapp, LPN | 417-841-3659 | mknapp@clinvest.com |
Contact: Deborah L Milligan, BS, RN | 417-841-3625 | dmilligan@clinvest.com |
United States, Missouri | |
Clinvest | Recruiting |
Springfield, Missouri, United States, 65807 | |
Contact: Deborah L Milligan, BS, RN 417-841-3625 dmilligan@clinvest.com | |
Contact: Mary E Beech, LPN 417-841-3618 mbeech@clinvest.com | |
Principal Investigator: Roger K Cady, M.D. | |
Sub-Investigator: Curtis P Schreiber, M.D. |
Responsible Party: | Clinvest, A Division of Banyan Group, Inc ( Roger K. Cady, M.D. ) |
Study ID Numbers: | Migraine IISP 33467 |
Study First Received: | October 13, 2008 |
Last Updated: | October 14, 2008 |
ClinicalTrials.gov Identifier: | NCT00772473 |
Health Authority: | United States: Institutional Review Board |
Calcitonin Gene-Related Peptide Calcitonin Migraine Disorders Headache Central Nervous System Diseases |
Headache Disorders, Primary Brain Diseases Salmon calcitonin Headache Disorders |
Vasodilator Agents Therapeutic Uses Physiological Effects of Drugs Nervous System Diseases |
Bone Density Conservation Agents Cardiovascular Agents Pharmacologic Actions |